Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 3/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29513573 | 1.00 | DGAT1 (0.36) | DGAT1MAPTPDE10ANPC1KLKB1 | |
| SCHEMBL30461589 | 0.82 | MTNR1A (0.37) | DGAT1MAPTPDE10ANPC1 | |
| SCHEMBL20455667 | 0.82 | DGAT1 (0.38) | DGAT1MAPTPDE10ANPC1 | |
| SCHEMBL25420978 | 0.82 | MTNR1A (0.37) | DGAT1MAPTPDE10ANPC1 | |
| SCHEMBL25345695 | 0.82 | DGAT1 (0.41) | DGAT1MAPTPDE10ANPC1 | |
| SCHEMBL29659291 | 0.82 | DGAT1 (0.38) | DGAT1MAPTPDE10ANPC1 | |
| SCHEMBL29513596 | 0.82 | DGAT1 (0.41) | DGAT1MAPTPDE10ANPC1 | |
| SCHEMBL25346708 | 0.81 | DGAT1 (0.34) | DGAT1MAPTPDE10ANPC1 | |
| SCHEMBL25346910 | 0.81 | DGAT1 (0.34) | DGAT1MAPTPDE10ANPC1 | |
| SCHEMBL25346315 | 0.80 | BRD4 (0.36) | DGAT1MAPTPDE10ANPC1KLKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240043420-A1 | 7-AZAINDOLE COMPOUNDS FOR INHIBITION OF BCR-ABL TYROSINE KINASES | ENLIVEN INC. | 2024-02-08 | — | — | US | disclosed |
| EP-4225741-A1 | 7-AZAINDOLE COMPOUNDS FOR INHIBITION OF BCR-ABL TYROSINE KINASES | Enliven Therapeutics, Inc. (US) | 2023-08-16 | — | — | EP | disclosed |
| WO-2022076973-A1 | 7-AZAINDOLE COMPOUNDS FOR INHIBITION OF BCR-ABL TYROSINE KINASES | ENLIVEN THERAPEUTICS, INC. (US) | 2022-04-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240043420-A1 | 7-AZAINDOLE COMPOUNDS FOR INHIBITION OF BCR-ABL TYROSINE KINASES | ABL1, ABL2, BCR | DGAT1 2534/4885MAPT 4135/4885PDE10A 1988/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.